Holen Sie sich die Stockscreener-App
0.5246
6.02%
-0.0336
Handel nachbörslich:
.54
0.0154
+2.94%
Schlusskurs vom Vortag:
$0.5582
Offen:
$0.58
24-Stunden-Volumen:
354.91K
Relative Volume:
0.98
Marktkapitalisierung:
$11.19M
Einnahmen:
$1.44M
Nettoeinkommen (Verlust:
$-21.34M
KGV:
-0.3923
EPS:
-1.3371
Netto-Cashflow:
$-17.38M
1W Leistung:
-4.37%
1M Leistung:
-2.82%
6M Leistung:
-29.88%
1J Leistung:
-60.56%
1-Tages-Spanne:
$0.5201
$0.58
1-Wochen-Bereich:
$0.50
$0.5923
52-Wochen-Spanne:
$0.492
$1.9198
Longeveron Inc Stock (LGVN) Company Profile
Firmenname
Longeveron Inc
Sektor
Branche
Telefon
305-302-7158
Adresse
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.5246 | 11.91M | 1.44M | -21.34M | -17.38M | -1.3371 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
Longeveron Inc Aktie (LGVN) Neueste Nachrichten
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Cantech Letter
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Longeveron Inc. (LGVN) asks shareholders to OK 1:5–1:20 reverse split to meet Nasdaq - Stock Titan
LGVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LGVN: Trial Results Encouraging - Research Tree
LGVN Should I Buy - Intellectia AI
Longeveron Reports Positive Phase 2b Clinical Trial Results - Intellectia AI
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy - Intellectia AI
Longeveron Shares Fall After Releasing Phase 2b Data From Age-Related Frailty Study - marketscreener.com
Longeveron publishes phase 2b stem cell trial results in journal - Investing.com
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty In Study - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron publishes phase 2b stem cell trial results in journal By Investing.com - Investing.com South Africa
Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - Bitget
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - The Manila Times
Stem cell therapy helps frailty patients walk farther in Longeveron trial - Stock Titan
Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN
Aug Movers: Can Longeveron Inc outperform in the next rallyEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Q1 Earnings Forecast for Longeveron Issued By Zacks Research - Defense World
Will Longeveron Inc. stock hit new highs in YEARMarket Performance Recap & Intraday High Probability Alerts - mfd.ru
Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday - Defense World
Trade Recap: Does Longeveron Inc offer margin of safetyJuly 2025 Sentiment & Free High Return Stock Watch Alerts - baoquankhu1.vn
LGVN SEC FilingsLongeveron Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Longeveron Inc. a strong candidate for buy and holdQuarterly Risk Review & Consistent Profit Focused Trading Strategies - mfd.ru
LGVN: New CEO and Fresh Cost Reductions - Research Tree
Longeveron Appoints Stephen Willard as CEO - citybiz
Surprises Report: Is Longeveron Inc stock a value trapJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Longeveron Appoints New CEO to Lead Pivotal Clinical Trials - National Today
Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail
Is Longeveron Inc. on track to beat earningsJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results - Investing.com Australia
Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results By Investing.com - Investing.com South Africa
Longeveron Appoints New CEO to Drive Growth - Intellectia AI
Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell - Quiver Quantitative
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - The Manila Times
New Longeveron CEO steps in as pivotal stem cell trial nears - Stock Titan
Gains Recap: Is Longeveron Inc. stock supported by strong fundamentalsEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru
Is Longeveron Inc. exposed to currency risksQuarterly Market Review & High Accuracy Trade Alerts - mfd.ru
How cyclical is Longeveron Incs revenue streamEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Is Longeveron Inc. still a buy after recent gains2025 Earnings Surprises & Consistent Return Investment Signals - mfd.ru
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - The Manila Times
Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan
Merger Talk: Is WABC part of any major indexVolume Spike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Catalysts: Will Longeveron Inc benefit from rising consumer demand2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Longeveron receives Japanese patent for stem cell potency assay methods By Investing.com - Investing.com South Africa
Longeveron receives Japanese patent for stem cell potency assay methods - Investing.com
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - The Manila Times
Longeveron prepares for pivotal HLHS therapy data with FDA meeting By Investing.com - Investing.com Nigeria
Gainers Report: Whats the outlook for CrowdStrike Holdings Incs sectorTake Profit & Growth Focused Stock Reports - baoquankhu1.vn
Published on: 2026-01-27 00:29:51 - baoquankhu1.vn
Longeveron Granted FDA Type C Meeting Ahead Of Pivotal ELPIS II Data For HLHS - Nasdaq
Finanzdaten der Longeveron Inc-Aktie (LGVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):